Diplomat Pharmacy Inc (NYSE:DPLO) has been assigned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $20.72.

DPLO has been the subject of a number of recent research reports. BidaskClub upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Friday, September 15th. Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. Needham & Company LLC restated a “buy” rating and issued a $23.75 price objective (up previously from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, October 10th. Finally, Mizuho set a $16.00 price objective on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research note on Tuesday, October 24th.

Diplomat Pharmacy (NYSE DPLO) opened at $20.77 on Friday. The company has a market cap of $1,451.85, a price-to-earnings ratio of 207.70, a P/E/G ratio of 3.39 and a beta of 0.62. Diplomat Pharmacy has a one year low of $12.25 and a one year high of $21.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.82 and a current ratio of 1.34.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the company earned $0.21 EPS. The business’s quarterly revenue was down 4.8% compared to the same quarter last year. equities analysts predict that Diplomat Pharmacy will post 0.85 earnings per share for the current year.

In related news, CFO Atul Kavthekar acquired 2,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were purchased at an average price of $15.00 per share, with a total value of $30,000.00. Following the acquisition, the chief financial officer now directly owns 2,000 shares in the company, valued at $30,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey G. Park acquired 3,000 shares of the firm’s stock in a transaction on Monday, November 20th. The shares were bought at an average cost of $15.46 per share, for a total transaction of $46,380.00. Following the acquisition, the director now owns 7,640 shares in the company, valued at $118,114.40. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 15,000 shares of company stock worth $228,780. Insiders own 30.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its stake in shares of Diplomat Pharmacy by 46.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after purchasing an additional 2,794 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Diplomat Pharmacy in the 3rd quarter valued at approximately $191,000. Piedmont Investment Advisors LLC acquired a new stake in Diplomat Pharmacy during the 3rd quarter worth approximately $216,000. First Allied Advisory Services Inc. acquired a new stake in Diplomat Pharmacy during the 2nd quarter worth approximately $183,000. Finally, Invictus RG raised its holdings in Diplomat Pharmacy by 24.4% during the 3rd quarter. Invictus RG now owns 13,820 shares of the company’s stock worth $286,000 after buying an additional 2,707 shares during the period. 72.21% of the stock is currently owned by institutional investors.

WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/05/diplomat-pharmacy-inc-dplo-given-consensus-rating-of-buy-by-brokerages.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.